| |  Online-Ressource |
|---|
| Verfasst von: | Braulke, Friederike [VerfasserIn]  |
|---|
| | Zettl, Florian [VerfasserIn] |
|---|
| | Ziepert, Marita [VerfasserIn] |
|---|
| | Viardot, Andreas [VerfasserIn] |
|---|
| | Kahl, Christoph [VerfasserIn] |
|---|
| | Prange-Krex, Gabriele [VerfasserIn] |
|---|
| | Korfel, Agnieszka [VerfasserIn] |
|---|
| | Dreyling, Martin [VerfasserIn] |
|---|
| | Bott, Alexander [VerfasserIn] |
|---|
| | Wedding, Ulrich [VerfasserIn] |
|---|
| | Reichert, Dietmar [VerfasserIn] |
|---|
| | de Wit, Maike [VerfasserIn] |
|---|
| | Hartmann, Frank [VerfasserIn] |
|---|
| | Poeschel, Viola [VerfasserIn] |
|---|
| | Schmitz, Norbert [VerfasserIn] |
|---|
| | Witzens-Harig, Mathias [VerfasserIn] |
|---|
| | Klapper, Wolfram [VerfasserIn] |
|---|
| | Rosenwald, Andreas [VerfasserIn] |
|---|
| | Wulf, Gerald [VerfasserIn] |
|---|
| | Altmann, Bettina [VerfasserIn] |
|---|
| | Trümper, Lorenz [VerfasserIn] |
|---|
| Titel: | First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma |
|---|
| Titelzusatz: | results of the B-R-ENDA trial |
|---|
| Verf.angabe: | Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | Dec 1, 2022 |
|---|
| Umfang: | 10 S. |
|---|
| Illustrationen: | Diagramme |
|---|
| Fussnoten: | Gesehen am 09.11.2023 |
|---|
| Titel Quelle: | Enthalten in: HemaSphere |
|---|
| Ort Quelle: | [Philadelphia, Pennsylvania] : Wolters Kluwer Health, 2017 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 6(2022), 12 vom: Dez., Artikel-ID e808, Seite 1-10 |
|---|
| ISSN Quelle: | 2572-9241 |
|---|
| Abstract: | The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61-80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64-80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76-80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option. |
|---|
| DOI: | doi:10.1097/HS9.0000000000000808 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1097/HS9.0000000000000808 |
|---|
| | Volltext: https://journals.lww.com/hemasphere/Fulltext/2022/12000/First_line_Treatment_With_Bendamustine_and.12.aspx |
|---|
| | DOI: https://doi.org/10.1097/HS9.0000000000000808 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1837269327 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
First-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma / Braulke, Friederike [VerfasserIn]; Dec 1, 2022 (Online-Ressource)
